Merck blood clot drug in limbo after mixed results

.

Merck blood clot drug in limbo after mixed results

On Saturday, drug-maker Merck & Co provided details about the last month-announced results of the tests of its experimental blood thinner `vorapaxar', revealing that despite the impressive effectiveness of the blood clot drug in bringing about a significant reduction in cardio vascular incidents in heart patients, worrisome bleeding was also witnessed in people who had suffered a stroke.

According to Merck, while the experimental drug, when combined with standard care, proved effective in bringing down the instances of cardio vascular events in heart patients, it also led to increased bleeding in some patients.

When Merck presented limited data from the study in February this year, the company had said that vorapaxar was proving to be an advantageous drug for heart patients. However, the drug-maker has now revealed that patients who had been administered vorapaxar were also experiencing excessive bleeding.

The Merck revelation, based on the results of the biggest heart-drug studies conducted thus far, implies that the vorapaxar blood clot preventer has shown mixed results; and has thus led to concerns whether the drug-maker will go ahead and seek regulatory approval for the drug.

Noting that the vorapaxar trial shows that there is "clearly a tradeoff here between the protective benefit and the risk of bleeding," Dr. David Morrow - who is a cardiologist from Brigham & Women's Hospital in Boston, and the leader of the trial - said: "Should the drug be approved, he said the challenge for doctors would be to withhold it from patients at likely higher bleeding risk."


Latest News

Oil Prices Drop Near Four-Month Low as Supply Glut and Chinese Economy Increases
Reportedly A.G. Lafley to Pass Reigns of P&G CEO to David Taylor
Baidu Profits in Second Quarter Offset by Higher Expenses
Economists Predict Solid Revenue Growth for Vermont
Swiss bank Vontobel Announces 24 Percent Increase in Profit in the First Half of
President Obama Visits Kenya, His Father’s Birth Place
National Highway Traffic Safety Administration Slaps $105M Fine on Fiat Chrysler
Wealthy, Well Educated People in Early 60’s More at Risk of Harmful Drinking
Amazon’s Strong Second Quarter Results Boost the Company’s Share
Weak PMI in China Raises Concern and Asian Shares Drop on Friday
Even with Lower Sales, Coca-Cola’s Profit Increases
Qualcomm Plans to Cut Jobs and May go in for a Spin Off